Member Info for avctIPmatters

FYI Global Market Size

1) triple negative breast cancer; (2) salivary gland cancer and (3) high grade soft tissue sarcoma. "

https://www.databridgemarketresearch.com/reports/global-triple-negative-breast-cancer-market

https://www.databridgemarketresearch.com/reports/global-salivary-gland-cancer-treatment-market#:~:text=The%20global%20salivary%20gland%20cancer%20treatment%20market%20size,during%20the%20forecast%20period%20of%202024%20to%202031.

https://www.databridgemarketresearch.com/reports/global-soft-tissue-sarcoma-market

Good Morning : 2024 Been a bit of a mixed bag . Science turns out to be far better than expected . That is a good thing . Will in time help treat a wider range of cancer patients with less side effects . The clinical trial contiinues and the IP asset value remains primed for future inflection points , obviously not as quick as some here wished .

Indeed current market value is very disappointing however intend to stay the course,.will give new management a chance to get better value for shareholders .

Good luck everyone have a good day .

gmcc

-------------------------

"Christina Coughlin, MD PhD, CEO of Avacta, commented: "We are encouraged by the anti-tumor activity observed in the Phase 1 dose escalation and RDE cohorts of the trial and the expansion cohorts are designed to build on that knowledge. Opening of the expansion cohorts represents a significant milestone in the development of FAP-Doxorubicin (AVA6000) in that we will now be able to assess the activity in specific indications to better plan Phase 2 development."

" The Phase 1b cohorts will enroll patients in three disease-specific cohorts including: (1) triple negative breast cancer; (2) salivary gland cancer and (3) high grade soft tissue sarcoma. "

Ondo InsurTech Plc

@OndoPlc

·

7h

#ONDO US home insurers suffer worst loss this century

@FT

https://ft.com/content/09a37793-7bea-4c90-a47f-4536405458e3

Who you gonna call?? #LeakBot

https://x.com/OndoPlc/status/1866758249808339333/photo/1

FYI

7:08 AM · Dec 11, 2024

·

1,048

Views

Ondo InsurTech Plc

@OndoPlc

#ONDO Expansion into the US 🇺🇸 has exceeded our expectations and is now positioning the US as a key market for our #LeakBot solution.

🔹This is the 1st step to build what has the potential to become a very significant, very large business with high margins & recurring revenues

https://x.com/OndoPlc/status/1866741871264841992

@JES1889 Sorry CSO for AffyXell Therapeutics not Avacta .

gmcc

Note they got around to updating website with change in Avacta Board of Directors

Simon Thomas Bennett

Christina Marie Coughlin

http://affyxell.com/company/people.php

Otherwise very silent on progress think there looking for a new CSO but no mention yet on website .

FYI --- Getting on with the day job :

https://www.linkedin.com/company/launch-diagnostics-deutschland-gmbh/

https://www.linkedin.com/pulse/respiratorische-infektionen-launch-diagnostics-deutschland-gmb-ipe3f/?trackingId=6qrsOM5KhBsMh3ziW55DHg%3D%3D

Respiratory infections

Launch Diagnostics Deutschland GmbH

63 followers

December 9, 2024

The respiratory season is in full swing and the activity of acute respiratory diseases in the population has increased compared to the previous week, according to the RKI. Both the incidence of acute respiratory diseases and flu-like illnesses remain at a comparatively high level. While this is typical for the season, the combination of influenza, RSV, and ongoing COVID-19 cases is increasing pressure on the healthcare system.

It's not too late to optimize your laboratory workflow this respiratory season – Launch Diagnostics Deutschland GmbH offers both targeted (influenza/RSV/SARS CoV-2) and advanced syndromic PCR panels for the detection of respiratory diseases."

FYI You can check the warrant price paid here :

https://find-and-update.company-information.service.gov.uk/company/13218816/filing-history

ONDO receive approx £118 k all helps the cashflow . Much more to come .

------------

"Date or period during which shares are allotted

From To 27/11/2024 28/11/2024

Class of Shares: ORDINARY

Currency: GBP

Number allotted 593333

Nominal value of each share 0.05

Amount paid: 0.2

Amount unpaid: 0

No shares allotted other than for cash "

gmcc

@ volmer : No problem ONDO listed on main board think management know what they are doing & saying .

Guess we wait & see :

Will also be a steady stream of warrants being exercised already happening all the way through to expiry dates .

Adds cash in ondo coffers ,

"As of 30 September 2024, and as at the current date, a total of 26.94m warrants remain outstanding, with a subscription value of up to approx. £6 million, as set out in the table below.

No of warrants Exercise price Subscription Value Expiry date

13,612,088 25p £3,403,022 21 March 2025

8,140,000 20p. £1,628,000 28 July 2025

5,191,669 20p £1,038,334 22 May 2026

Total 26,943,757 Total Value £6,069,356"

gmcc

Sorry that reply was for volmer fund raise comment :

-------------

#ONDO Chairman Mark Wood CBE explains how ONDO is expanding into new states in the 🇺🇸 by leveraging advanced customer orders that fund manufacturing costs & infrastructure without straining working capital.

🔹These prepaid orders mean expansion is funded by the terms of trade

https://x.com/OndoPlc/status/1858868967789515054

gmcc

" I think we will find additional working capital funding is needed and that a fund raise will come in H1 2025, probably around the financial year end."

Chairman /CEO/CFO say otherwise " Funding not required " in recent RNS /videos /presentations .

Better to look forward not back

"Looking Ahead

The outlook for Ondo is exciting. In the second half of 2024, we will see an unprecedented level of activity, with new campaigns and partnerships launching across all geographies.

In the U.S. our goal is to establish LeakBot as the industry-standard market leading solution for U.S. insurers to predict and prevent water damage claims. We are particularly focused on sustaining the momentum we've built in the U.S., leveraging the repeat prepayment model to fund further growth. This innovative contractual framework ensures that our expansion is largely self-funded, enabling us to deploy LeakBot at scale without the need for additional capital. EBITDA trading is in sight in the second half of 2025 without the need for any additional working capital funding."

gmcc

FYI

https://avacta.com/investors/investor-resources/ 0 2024-12-09 15:56 +00:00

https://avacta.com/our-science/ 0 2024-12-09 16:07 +00:00

IF you don't blink Coris products highlighted in this video .( 40 secs )

https://www.linkedin.com/company/excellence-diagnostic/posts/

Excellence DiagnosticExcellence Diagnostic

384 followers384 followers

1d • 1 day ago

Follow

It was an honor to be a part of the 3rd Conference of *ARMED FORCES LABORATORIES FOR MEDICAL RESEARCH AND BLOOD BANK (AFLMR).

We want to thank the AFLMR team for allowing us to contribute to such a great event.

Thanks to our team for their dedication and professional performance.

Finally, we thank our partners, Autobio, Precision Biosensor, and Coris BioConcept, for their pioneering solutions with high quality that make a difference! Autobio Diagnostics, Precision Biosensor, CORIS BIOCONCEPT

https://misr2000.com/event/3rd-armed-forces/

Hi Tim I somehow managed to insert my email details /contact tel number on a post so asked Admin to remove that AVCT message however it remained visible for too long so asked Admin to delete gmcc account . Not really sure if anyone noticed ,anyway a shame as i lost all my history .

Thought as i keep banging on about how the IP matters not the SP would use avctipmatters however on reflection bit silly for my other stock posts.

gmcc

Nice to see you back .

FYI https://www.investormeetcompany.com/investor/meetings/interim-results-410

gmcc

As a minimum as per presentations :

"Identify RDE and Open Phase 1b Expansions in 3 Indications 2H 2024 ----(RDE cohorts Phase 1 AVA6000 FPI)

Candidate Selection of pre|CISION FAP-EXd (AVA6103) program 2H 2024"

---------

Be good to get some other communication to end the year on a high note - my AVCT paper deficit needs a positive boost .

Good luck everyone

gmcc

Yes Craig normally very careful in his remarks & respectful of main market reporting rules so must be must be feeling very confident on pipeline orders very bullish indeed .

gmcc

Good Morning - Steady increase in market cap value will do nicely .

7:41 AM · Dec 6, 2024

"Ondo InsurTech Plc

@OndoPlc

#ONDO's customer base and revenue have significantly grown over 6 months, with a 36% increase in registered customers to 114,000 and a 42% annualized revenue increase to $3.4M

📈The US market is particularly attractive due to the larger claims costs per home that #LeakBot predicts and prevents

#LeakBot #InsurTech"

https://x.com/OndoPlc/status/1864938269487583256

BLOG

https://avacta.com/category/blogs/